Brind.
  1. BioNTech acquired CureVac for mRNA technology and entered a collaboration to co-develop BNT327.

BioNTech included CureVac operations in its expenses.

2 reports, 2 independent Updated Aug 11
Gone quiet
Reports
2
Developments
2
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

BioNTech included CureVac operations in its expenses.

Who's involved

What this event is mainly about
CureVac

How it developed

Newest first. Tap a step to see who reported it.
  1. Pfizer made a prior-year payment regarding the inclusion of CureVac operations.1 source
  2. BioNTech integrates CureVac operations into its financial structure.1 source

Keep exploring

Part of

BioNTech acquired CureVac for mRNA technology and entered a collaboration to co-develop BNT327. All 1 developments

The entities involved

  • CureVac

    biopharmaceutical company in Germany

    Nothing else this week.

Coverage

Newest first; wire copies grouped